NM_000051.4:c.7618G>A
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP6
The NM_000051.4(ATM):c.7618G>A(p.Val2540Ile) variant causes a missense change. The variant allele was found at a frequency of 0.000085 in 1,611,924 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. V2540V) has been classified as Likely benign.
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.7618G>A | p.Val2540Ile | missense_variant | Exon 51 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000132 AC: 20AN: 151748Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000438 AC: 11AN: 251002Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135706
GnomAD4 exome AF: 0.0000801 AC: 117AN: 1460176Hom.: 0 Cov.: 31 AF XY: 0.0000881 AC XY: 64AN XY: 726360
GnomAD4 genome AF: 0.000132 AC: 20AN: 151748Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74094
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Uncertain:5
This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 2540 of the ATM protein (p.Val2540Ile). This variant is present in population databases (rs35203200, gnomAD 0.009%). This missense change has been observed in individual(s) with gastric cancer, breast cancer, ovarian cancer, chronic lymphocytic leukemia, pancreatic cancer, melanoma, and colorectal cancer (PMID: 25186627, 26689913, 26976419, 27978560, 28591191, 28652578, 29360161, 33850299). ClinVar contains an entry for this variant (Variation ID: 141579). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt ATM protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. -
The ATM c.7618G>A; p.Val2540Ile variant (rs35203200) is reported in the literature in individuals with breast, ovarian, stomach, or colorectal cancer (Lu 2015, Pearlman 2017, Stafford, Tung 2016) but has also been reported in an unaffected control (Tavtigian 2009). This variant is classified as uncertain in ClinVar (Variation ID: 141579), and found in the general population with an overall allele frequency of 0.005% (13/276580 alleles) in the Genome Aggregation Database. The valine at codon 2540 is moderately conserved, but computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of this variant is uncertain at this time. REFERENCES Lu C et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015 Dec 22;6:10086. Pearlman R et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2017 Apr 1;3(4):464-471. Stafford JL et al. Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. PLoS One. 2017 Jun 7;12(6):e0178450. Tavtigian SV et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009 Oct;85(4):427-46. Tung N et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016 May 1;34(13):1460-8. -
- -
not provided Uncertain:4Benign:1
ATM: BP4 -
The frequency of this variant in the general population, 0.0001 (13/128932 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals with breast/ovarian cancer (PMIDs: 29522266 (2018), 29360161 (2018), 28779002 (2017), 26976419 (2016), 25186627 (2015)), colorectal cancer (PMID: 27978560 (2016)), stomach cancer (PMID: 26689913 (2015)), lymphocytic leukemia (PMID: 28652578 (2017)), as well as in control individuals (PMIDs: 28779002 (2017), 19781682 (2009), 16832357 (2006)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate reduced HDR activity, reduced cell viability, and defects in kinase activity (PMID: 35354106); In silico analysis indicates that this missense variant does not alter protein structure/function; Observed in individuals with breast, ovarian, rectal, and other cancers, but also in unaffected controls (PMID: 19781682, 26689913, 26976419, 28779002, 27978560, 28591191, 28652578, 29522266, 29641532, 30303537, 30374176, 34326862, 34262154, 33471991); This variant is associated with the following publications: (PMID: 26976419, 30374176, 31920950, 30303537, 19781682, 26689913, 22529920, 27978560, 28591191, 27720647, 28779002, 29522266, 28652578, 29596542, 29641532, 23532176, 33471991, 34326862, 34262154, 33850299, 35354106) -
- -
PM2_moderate, PS3_moderate -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:2
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
not specified Uncertain:2
Variant summary: ATM c.7618G>A (p.Val2540Ile) results in a conservative amino acid change located in the PIK-related kinase, FAT domain (IPR003151) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 252044 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in ATM causing Ataxia-Telangiectasia (4.8e-05 vs 0.004), allowing no conclusion about variant significance. c.7618G>A has been reported in the literature in individuals affected with breast cancer (e.g. Tung_2015, Tung_2016, Hauke_2018, Girard_2019), ovarian cancer (e.g. Stafford_2017), CLL (e.g. Tiao_2017), colorectal cancer (e.g. Pearlman_2016), and pancreatic cancer (e.g. Dudley_2018), but also in healthy controls (e.g. Renwick_2006, Tavtigian_2009). The variant has also been reported in an individual with dystonia (e.g. Pogoda_2019). These reports do not provide unequivocal conclusions about association of the variant with Ataxia-Telangiectasia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. These laboratories cited the variant as uncertain significance (n=7) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. -
- -
Familial cancer of breast Uncertain:1Benign:1
- -
This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -
Breast and/or ovarian cancer Uncertain:1
- -
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Uncertain:1
- -
ATM-related disorder Uncertain:1
The ATM c.7618G>A variant is predicted to result in the amino acid substitution p.Val2540Ile. This variant has been reported in patients with colorectal cancer (eTable 2, Pearlman et al. 2017. PubMed ID: 27978560), breast cancer (Tung et al 2016. PubMed ID: 26976419), and ovarian cancer (Stafford et al. 2017. PubMed ID: 28591191). However, this variant was also reported in a control individual in a breast cancer study (Table S2, Tavtigian et al. 2009. PubMed ID: 19781682). This variant is reported in 0.010% of alleles in individuals of European (non-Finnish) descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from likely benign to uncertain significance (https://www.ncbi.nlm.nih.gov/clinvar/variation/141579/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at